(MY-doh-STAW-rin)
This page contains brief information about midostaurin and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Midostaurin is approved to treat:
- Acute myeloid leukemia (AML). It is used with cytarabine and daunorubicin hydrochloride in newly diagnosed adults whose cancer has a mutation in the FLT3 gene.
- Aggressive systemic mastocytosis, systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia in adults.
Midostaurin is also being studied in the treatment of other conditions and types of cancer.
More About Midostaurin
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Midostaurin – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Midostaurin – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
